Reviva Pharmaceuticals Holdings, Inc.RVPHNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank28
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P28
Within normal range
vs 3Y Ago
-0.8x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-19.16%
Q2 2025-3.15%
Q1 202551.19%
Q4 2024-0.03%
Q3 2024-36.97%
Q2 202419.04%
Q1 202441.40%
Q4 2023-24.08%
Q3 2023-35.32%
Q2 2023105.21%
Q1 20231.63%
Q4 202217.47%
Q3 202225.06%
Q2 2022-37.96%
Q1 202224.45%
Q4 202123.58%
Q3 2021-25.59%
Q2 2021-4.40%
Q1 2021181.18%
Q4 20203.00%
Q3 2020-30.99%
Q2 2020113.50%
Q1 20200.00%
Q4 20190.00%
Q3 20190.00%
Q2 2019-100.00%
Q1 20190.00%
Q4 20180.00%
Q3 2018-100.00%
Q2 20180.00%